Skip to main content

Advertisement

SpringerLink
Log in

Review of Recommended Treatment of Uterine Carcinosarcoma

  • Gynecologic Cancers (RJ Morgan, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Surgery is the primary treatment for uterine carcinosarcoma (UCS). Lymphadenectomy should be performed for staging purposes in tumors apparently confined to the uterus. Most studies found that lymphadenectomy is of therapeutic value. The therapeutic value of cytoreduction to no residual macroscopic disease in advanced UCS is based mostly on small retrospective uncontrolled studies. Postoperative adjuvant therapy should be considered for all stages of UCS. Adjuvant pelvic radiotherapy may reduce locoregional recurrences. However, this does not translate into improved overall survival since most recurrences are distant outside the irradiated field, and the survival rates remain poor, the 5-year overall survival being about 50 %. Several adjuvant platin-based combination chemotherapy schedules such as cisplatin/ifosfamide, ifosfamide/paclitaxel, and paclitaxel/carboplatin have been found to be an effective mode of adjuvant treatment. Multimodal therapy (i.e., adjuvant chemotherapy plus radiotherapy) has also been shown to be effective. Most studies dealing with adjuvant treatment are retrospective and prospective randomized controlled trials (i.e., phase III studies) comparing that between the various adjuvant chemotherapy schedules and between them and multimodal treatment are lacking. Quality of life with the various treatment modalities needs also to be assessed. An effective targeted therapy has so far not been found. In spite of the multiple studies with regard to the treatment of UCS published during the last 15 years, the optimal management of UCS is still not established.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Harlow BL, Weiss NS, Lofton S. The epidemiology of sarcomas of the uterus. J Natl Cancer Inst. 1986;76:399–402.

    CAS  PubMed  Google Scholar 

  2. Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol. 2004;93:204–8.

    Article  PubMed  Google Scholar 

  3. Sherman ME, Devesa SS. Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus. Cancer. 2003;98:176–86.

    Article  PubMed  Google Scholar 

  4. Erickson BK, Doo DW, Zhang B, Huh WK, Leath 3rd CA. Black race independently predicts worse survival in uterine carcinosarcoma. Gynecol Oncol. 2014;133:238–41.

    Article  PubMed  Google Scholar 

  5. Yamada SD, Burger RA, Brewster WR, Anton D, Kohler MF, Monk BJ. Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer. 2000;88:2782–6.

    Article  CAS  PubMed  Google Scholar 

  6. Gokce ZK, Turan T, Karalok A, Tasci T, Ureyen I, Ozkaya E, et al. Clinical outcomes of uterine carcinosarcoma: results of 94 patients. Int J Gynecol Cancer. 2015;25:279–87.

    Article  PubMed  Google Scholar 

  7. Temkin SM, Hellmann M, Lee YC, Abulafia O. Early-stage carcinosarcoma of the uterus: the significance of lymph node count. Int J Gynecol Cancer. 2007;17:215–9.

    Article  CAS  PubMed  Google Scholar 

  8. Rovirosa A, Ascaso C, Arenas M, Ríos I, Del Pino M, Ordi J, et al. Pathologic prognostic factors in stage I-III uterine carcinosarcoma treated with postoperative radiotherapy. Arch Gynecol Obstet. 2014;290:329–34.

    PubMed  Google Scholar 

  9. Ferguson SE, Tornos C, Hummer A, Barakat RR, Soslow RA. Prognostic features of surgical stage I uterine carcinosarcoma. Am J Surg Pathol. 2007;31:653–61.

    Article  Google Scholar 

  10. Djordjevic B, Gien LT, Covens A, Malpica A, Khalifa MA. Polypoid or non polypoid? A novel dichotomous approach to uterine carcinosarcoma. Gynecol Oncol. 2009;115:32–6.

    Article  CAS  PubMed  Google Scholar 

  11. Gonzalez Bosquet J, Terstriep SA, Cliby WA, Brown-Jones M, Kaur JS, Podratz KC, et al. Keeney GL. The impact of multi-modal therapy on survival for uterine carcinosarcomas. Gynecol Oncol. 2010;116:419–23.

    Article  PubMed  Google Scholar 

  12. El-Nashar SA, Mariani A. Uterine carcinosarcoma. Clin Obstet Gynecol. 2011;54:292–304.

    Article  PubMed  Google Scholar 

  13. McCluggage WG. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer. 2002;12:687–90.

    Article  CAS  PubMed  Google Scholar 

  14. de Jong RA, Nijman HW, Wijbrandi TF, Reyners AK, Boezen HM, Hollema H. Molecular markers and clinical behavior of uterine carcinosarcomas: focus on the epithelial tumor component. Mod Pathol. 2011;24:1368–79.

    Article  PubMed  CAS  Google Scholar 

  15. Abargel A, Avinoach I, Kravtsov V, Boaz M, Glezerman M, Menczer J. Expression of p27 and p53: comparative analysis of uterine carcinosarcoma and endometrial carcinoma. Int J Gynecol Cancer. 2004;14:354–9.

    Article  CAS  PubMed  Google Scholar 

  16. Menczer J, Kravtsov V, Levy T, Berger E, Glezerman M, Avinoach I. Expression of c-kit in uterine carcinosarcoma. Gynecol Oncol. 2005;96:210–5.

    Article  CAS  PubMed  Google Scholar 

  17. Menczer J, Schreiber L, Sukmanov O, Kravtsov V, Berger E, Golan A, et al. COX-2 expression in uterine carcinosarcoma. Acta Obstet Gynecol Scand. 2010;89:120–5.

    Article  PubMed  Google Scholar 

  18. Buza N, Tavassoli FA. Comparative analysis of P16 and P53 expression in uterine malignant mixed mullerian tumors. Int J Gynecol Pathol. 2009;28(28):514–21.

    Article  PubMed  Google Scholar 

  19. Raspollini MR, Susini T, Amunni G, Paglierani M, Taddei A, et al. COX- 2, c-KIT and HER2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies? Gynecol Oncol. 2005;96:159–67.

    Article  CAS  PubMed  Google Scholar 

  20. Sawada M, Tsuda H, Kimura M. Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial mesenchymal components in uterine carcinosarcoma. Cancer Sci. 2003;94:986–91.

    Article  CAS  PubMed  Google Scholar 

  21. Livasy CA, Reading FC, Moore DT, Boggess JF, Lininger RA. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. Gynecol Oncol. 2006;100:101–6.

    Article  CAS  PubMed  Google Scholar 

  22. Winter III WE, Seidman JD, Krivak TC, Chauhan S, Carlson JW, Rose GS, et al. Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpus. Gynecol Oncol. 2003;91:3–8.

    Article  CAS  PubMed  Google Scholar 

  23. Leath III CA, Straughn Jr JM, Conner MG, Barnes III MN, Alvarez RD, Partridge EE, et al. Immunohistochemical evaluation of the c-kit proto-oncogene in sarcomas of the uterus: a case series. J Reprod Med. 2004;49:71–5.

    PubMed  Google Scholar 

  24. Rushing RS, Shajahan S, Chendil D, Wilder JL, Pulliam J, Lee EY, et al. Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT. Gynecol Oncol. 2003;91:9–14.

    Article  CAS  PubMed  Google Scholar 

  25. Nakayama M, Mitsuhashi T, Shimizu Y, Ban S, Ogawa F, Ishihara O, et al. Immunohistochemical evaluation of KIT expression in sarcomas of the gynecologic region. Int J Gynecol Pathol. 2006;25:70–6.

    Article  PubMed  Google Scholar 

  26. Adams SF, Hickson JA, Hutto JY, Montag AG, Lengyel E, Yamada SD. PDGFR alpha as a potential therapeutic target in uterine sarcomas. Gynecol Oncol. 2007;104:524–8.

    Article  CAS  PubMed  Google Scholar 

  27. Erdogan G, Bassorgun CI, Pestereli HE, Simsek T, Karaveli S. C-kit protein expression in uterine and ovarian mesenchymal tumours. APMIS. 2007;115:204–9.

    Article  CAS  PubMed  Google Scholar 

  28. Cimbaluk D, Rotmensch J, Scudiere J, Gown A, Bitterman P. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets. Gynecol Oncol. 2007;105:138–44.

    Article  CAS  PubMed  Google Scholar 

  29. Saglam O, Husain S, Toruner G. AKT, EGFR, C-ErbB-2, and C-kit expression in uterine carcinosarcoma. Int J Gynecol Pathol. 2013;32:493–500.

    Article  CAS  PubMed  Google Scholar 

  30. Bashir S, Jiang G, Joshi A, Miller Jr C, Matrai C, Yemelyanova A, et al. Molecular alterations of PIK3CA in uterine carcinosarcoma, clear cell, and serous tumors. Int J Gynecol Cancer. 2014;24:1262–7.

    Article  PubMed  Google Scholar 

  31. Holmes BJ, Gown AM, Vang R, Ronnett BM, Yemelyanova A. PAX8 Expression in uterine malignant mesodermal mixed tumor (carcinosarcoma). Int J Gynecol Pathol. 2014;33:425–31.

    Article  CAS  PubMed  Google Scholar 

  32. South SA, Hutton M, Farrell C, Mhawech-Fauceglia P, Rodabaugh KJ. Uterine carcinosarcoma associated with hereditary nonpolyposis colorectal cancer. Obstet Gynecol. 2007;110:543–5.

    Article  PubMed  Google Scholar 

  33. Callister M, Ramondetta LM, Jhingran A, Burke TW, Eifel PJ. Malignant mixed mullerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys. 2004;58:786–96.

    Article  PubMed  Google Scholar 

  34. McCluggage WG, Abdulkader M, Price JH, Kelehan P, Hamilton S, Beattie J, et al. Uterine carcinosarcomas in patients receiving tamoxifen. A report of 19 cases. Int J Gynecol Cancer. 2000;10:280–4.

    Article  PubMed  Google Scholar 

  35. Kloos I, Delaloge S, Pautier P, Di Palma M, Goupil A, Duvillard P, et al. Tamoxifen-related uterine carcinosarcomas occur under/after prolonged treatment: report of five cases and review of the literature. Int J Gynecol Cancer. 2002;12:496–500.

    Article  CAS  PubMed  Google Scholar 

  36. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009;105:103–4.

    Article  PubMed  Google Scholar 

  37. Sagr ER, Denschlag D, Kerim-Dikeni A, Stanimir G, Gitsch G, Gilbert L. Prognostic factors and treatment-related outcome in patients with uterine papillar serous carcinoma. Anticancer Res. 2007;27:1213–7.

    PubMed  Google Scholar 

  38. Bansal N, Herzog TJ, Seshan VE, Schiff PB, Burke WM, Cohen CJ, et al. Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior. Obstet Gynecol. 2008;112:64–70.

    Article  PubMed  Google Scholar 

  39. Akahira J, Tokunaga H, Toyoshima M, Takano T, Nagase S, Yoshinaga K, et al. Prognoses and prognostic factors of carcinosarcoma, endometrial stromal sarcoma and uterine leiomyosarcoma: a comparison with uterine endometrial adenocarcinoma. Oncology. 2006;71:333–40.

    Article  PubMed  Google Scholar 

  40. Zhang C, Hu W, Jia N, Li Q, Hua K, Tao X, et al. Uterine Carcinosarcoma and High-Risk Endometrial Carcinomas: a clinicopathological Comparison. Int J Gynecol Cancer. 2015;25:629–36. Carcinosarcomas exhibited significantly poorer outcomes than did G3 endometrial endometrioid carcinomas and clear cell adenocarcinomas. Therefore, it seems reasonable to regard carcinosarcomas as a particular type among high-risk epithelial endometrial carcinomas.

    Article  PubMed  Google Scholar 

  41. Desai NB, Kollmeier MA, Makker V, Levine DA, Abu-Rustum NR, Alektar KM. Comparison of outcomes in early stage Uterine carcinosarcoma and uterine serous carcinoma. Gynecol Oncol. 2014;135:49–53.

    Article  PubMed  Google Scholar 

  42. Tanaka YO, Tsunoda H, Minami R, Yoshikawa H, Minami M. Carcinosarcoma of the uterus: MR findings. J Magn Reson Imaging. 2008;28:434–9.

    Article  PubMed  Google Scholar 

  43. Santos P. Cunha TMUterine sarcomas: clinical presentation and MRI features. Diagn Interv Radiol. 2015;21:4–9.

    Article  PubMed Central  PubMed  Google Scholar 

  44. Huang GS, Chiu LG, Gebb JS, Gunter MJ, Sukumvanich P, Goldberg GL, et al. Serum CA125 predict extra uterine disease and survival in uterine carcinosarcoma. Gynecol Oncol. 2007;107:513–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  45. Thomakos N, Rodolakis A, Zagouri F, Zacharakis D, Sotiropoulou M, Akrivos N, et al. Serum CA 125, CA 15-3, CEA, and CA 19-9: a prognostic factor for uterine carcinosarcomas? Arch Gynecol Obstet. 2013;287:97–102.

    Article  CAS  PubMed  Google Scholar 

  46. Garg G, Kruger M, Christensen C, Deppe G, Toy EP. Stage III uterine carcinosarcoma: 2009 International Federation of Gynecology and Obstetrics Staging System and Prognostic Determinants. Int J Gynecol Cancer. 2011;21:1606–12.

    Article  PubMed  Google Scholar 

  47. Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH. The role of pelvic and/or para-aortic lymphadenectomy in surgical management of apparently early carcinosarcoma of uterus. Ann Surg Oncol. 2010;17:861–8.

    Article  PubMed  Google Scholar 

  48. Hoellen F, Waldmann A, Benthin S, Hanker L, Rody A, Fischer D. The role of lymphadenectomy in uterine sarcoma: a clinical practical approach based on retrospective analysis. Anticancer Res. 2014;34:985–93.

    PubMed  Google Scholar 

  49. Nemani D, Mitra N, Guo M, Lin L. Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Oncol. 2008;111:82–8.

    Article  PubMed  Google Scholar 

  50. Vorgias G, Fotiou S. The role of lymphadenectomy in uterine carcinosarcomas (malignant mixed Mullerian tumours): a critical literature review. Arch Gynecol Obstet. 2010;282:659–64. Lymphadenectomy beyond staging information seems to offer a measurable survival benefit.

    Article  CAS  PubMed  Google Scholar 

  51. Alagkiozidis I, Grossman A, Tang NZ, Weedon J, Mize B, Salame G, et al. Survival impact of cytoreduction to microscopic disease for advanced stage cancer of the uterine corpus: a retrospective cohort study. Int J Surg. 2015;4:61–6.

    Article  Google Scholar 

  52. Tanner EJ, Leitao Jr MM, Garg K, Chi DS, Sonoda Y, Gardner GJ, et al. The role of cytoreductive surgery for newly diagnosed advanced stage uterine carcinosarcoma. Gynecol Oncol. 2011;123:548–52.

    Article  PubMed  Google Scholar 

  53. Machida H, Takahashi K, Nomura H, Matoda M, Omatsu K, Kato K, et al. Impact of multimodal therapy on the survival of patients with newly diagnosed uterine carcinosarcoma. Eur J Gynaecol Oncol. 2013;34:291–5.

    CAS  PubMed  Google Scholar 

  54. Sorbe B, Paulsson G, Andersson S, Steineck G. A population-based series of uterine carcinosarcomas with long-term follow-up. Acta Oncol. 2013;52:759–66. Radiotherapy seems to be the most important constituent of adjuvant therapy of uterine carcinosarcoma.

    Article  PubMed  Google Scholar 

  55. Khoury-Collado F, Einstein MH, Bochner BH, Alektiar KM, Sonoda Y, Abu Rustum NR, et al. Pelvic exenteration with curative intent for recurrent uterine malignancies. Gynecol Oncol. 2012;124:42–7.

    Article  PubMed  Google Scholar 

  56. Leath 3rd CA, Numnum TM, Kendrick 4th JE, Frederick PJ, Rocconi RP, Conner MG, et al. Patterns of failure for conservatively managed surgical stage I uterine carcinosarcoma: implications for adjuvant therapy. Int J Gynecol Cancer. 2009;19:888–91.

    Article  PubMed  Google Scholar 

  57. Dusenbery KE, Potish RA, Argenta PA, Judson PL. On the apparent failure of adjuvant pelvic radiotherapy to improve survival for women with uterine sarcomas confined to the uterus. Am J Clin Oncol. 2005;28:295–300.

    Article  PubMed  Google Scholar 

  58. Yu T, Kim HJ, Wu HG, Ha SW, Song YS, Park NH, et al. See comment in PubMed Commons belowOutcome analysis in patients with uterine sarcoma. Radiat Oncol J. 2015;33:29–35. Postoperative whole pelvic radiotherapy significantly reduces pelvic failure.

    Article  PubMed Central  PubMed  Google Scholar 

  59. Brown LC, Petersen IA, Haddock MG, Bakkum-Gamez JN, Lee LJ, Cimbak NC, et al. Vaginal brachytherapy for early-stage carcinosarcoma of the uterus. Brachytherapy. 2015;14:433–9. Patients with early-stage (I-II) uterine carcinosarcoma treated with vaginal brachytherapy have relatively high rates of local and distant relapse.

    Article  PubMed  Google Scholar 

  60. Reed NS, Mangioni C, Malmström H, Scarfone G, Poveda A, Pecorelli S, et al. Phase III randomised study to evaluate the role of adjuvant radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer. 2008;44:808–18. An increased local control for carcinosarcoma patients receiving adjuvant radiation was found without an effect on either overall or progression free survival.

    Article  CAS  PubMed  Google Scholar 

  61. Sampath S, Schultheiss TE, Ryu JK, et al. The role of adjuvant radiation in uterine sarcomas. Int J Radiat Oncol Biol Phys. 2010;76:728–34.

    Article  PubMed  Google Scholar 

  62. Park HJ, Kim HJ, Wu HG, Kim H, Ha SW, Kang SB, et al. The influence of adjuvant radiotherapy on patterns of failure and survivals in uterine carcinosarcoma. Radiat Oncol J. 2011;29:228–35.

    Article  PubMed Central  PubMed  Google Scholar 

  63. Clayton Smith D, Keneth MacDonald O, Gaffney DK. The impact of adjuvant radiation therapy on survival in women with uterine carcinosarcoma. Radiother Oncol. 2008;88:227–32.

    Article  CAS  PubMed  Google Scholar 

  64. Wright JD, Seshan VE, Shah M, Schiff PB, Burke WM, Cohen CJ, et al. The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma. Am J Obstet Gynecol. 2008;199:536.e1–8.

    Article  Google Scholar 

  65. Denschlag D, Masoud I, Stanimir G, Gilbert L. Prognostic factors and outcome in women with uterine sarcoma. Eur J Surg Oncol. 2007;33:91–5.

    Article  CAS  PubMed  Google Scholar 

  66. Le T. Adjuvant pelvic radiotherapy for uterine carcinosarcoma in a high risk population. Eur J Surg Oncol. 2001;27:282–5.

    Article  CAS  PubMed  Google Scholar 

  67. Wolfson AH, Brady MF, Rocereto T, Mane RS, Lee YC, Fuloran RJ, et al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna as postsurgical therapy in stage I–IV carcinosarcoma of the uterus. Gynecol Oncol. 2007;107:177–85.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  68. Cantrell LA, Havrilesky L, Moore DT, O’Malley D, Liotta M, Secord AA, et al. A multiinstitutional cohort study of adjuvant therapy in stage I–II uterine carcinosarcoma. Gynecol Oncol. 2012;127:22–6.

    Article  PubMed  Google Scholar 

  69. Garg G, Yee C, Schwartz K, Mutch DG, Morris RT, Powell MA. Patterns of care, predictors, and outcomes of chemotherapy in elderly women with early stage uterinecarcinosarcoma: a population-based analysis. Gynecol Oncol. 2014;133:242–9. Adjuvant chemotherapy was not associated with any significant survival benefit in elderly women with early stage uterine carcinosarcoma.

    Article  PubMed Central  PubMed  Google Scholar 

  70. Ramondetta LM, Burke TW, Jhingran A, Schmandt R, Bevers MW, Wolf JK, et al. A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed müllerian tumors with evaluation of potential molecular targets. Gynecol Oncol. 2003;90:529–36.

    Article  CAS  PubMed  Google Scholar 

  71. Sutton G, Brunetto VL, Kilgore L, Sopper JT, McGehee R, Olt G, et al. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group Study. Gynecol Oncol. 2000;79:147–53.

    Article  CAS  PubMed  Google Scholar 

  72. Sutton G, Kauderur J, Carson LF, Lentz SS, Whitney W, Gallion H, et al. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I and II carcinosarcomas (MMT) of the uterus: a Gynaecologic Oncology Group study. Gynecol Oncol. 2005;96:630–4.

    Article  CAS  PubMed  Google Scholar 

  73. Homesely HD, Filiaci V, Markman M, Bittermann P, Eaton L, Kilgore LC, et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcomas. Gynaecologic Oncology Group Study. J Clin Oncol. 2007;25:526–31.

    Article  CAS  Google Scholar 

  74. Galaal K, Godfrey K, Naik R, Kucukmetin A, Bryant A. Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. Cochrane Database Syst Rev. 2011;19(1):CD006812.

    Google Scholar 

  75. Galaal K, van der Heijden E, Godfrey K, Naik R, Kucukmetin A, Bryant A, et al. Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. Cochrane Database Syst Rev. 2013;2:CD006812.

    PubMed  Google Scholar 

  76. Toyoshima M, Akahira J, Matsunaga G, Niikura H, Ito K, Yaegashi N, et al. Clinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma of the uterus. Gynecol Oncol. 2004;94:774–8.

    Article  CAS  PubMed  Google Scholar 

  77. Hoskins PJ, Le N, Ellard S, Lee U, Martin LA, Swenerton KD, et al. Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors The British Columbia Cancer Agency experience. Gynecol Oncol. 2008;108:58–62.

    Article  CAS  PubMed  Google Scholar 

  78. Makker V, Abu-Rustum NR, Alektiar KM, Aghajanian CA, Zhou Q, Iasonos A, et al. A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma. Gynecol Oncol. 2008;111:249–54.

    Article  PubMed Central  PubMed  Google Scholar 

  79. Powell MA, Filiaci VL, Rose PG, Mannel RS, Hanjani P, Degeest K, et al. Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. J Clin Oncol. 2010;28:2727–31.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  80. Otsuki A, Watanabe Y, Nomura H, Futagami M, Yokoyama Y, Shibata K, et al. Paclitaxel and carboplatin in patients with completely or optimally resected carcinosarcoma of the uterus: a phase II trial by the Japanese Uterine Sarcoma Group and the Tohoku Gynecologic Cancer Unit. Int J Gynecol Cancer. 2015;25:92–7. The combination of paclitaxel and carboplatin is a feasible and effective postoperative adjuvant therapy for patients with completely or optimally resected uterine carcinosarcoma.

    Article  PubMed  Google Scholar 

  81. Lacour RA, Euscher E, Atkinson EN, Sun CC, Ramirez PT, Coleman RL, et al. A phase II trial of paclitaxel and carboplatin in women with advanced or recurrent uterine carcinosarcoma. Int J Gynecol Cancer. 2011;21:517–22.

    Article  PubMed  Google Scholar 

  82. Takano T, Otsuki T, Tokunaga H, Toyoshima M, Utsunomiya H, Nagase S, et al. Paclitaxel-carboplatin for advanced or recurrent carcinosarcoma of the uterus: the Japan Uterine Sarcoma Group and Tohoku Gynecologic Cancer Unit Study. Int J Clin Oncol. 2014;19:1052–8.

    Article  CAS  PubMed  Google Scholar 

  83. Pectasides D, Pectasides E, Papaxoinis G, Xiros N, Sykiotis C, Papachristodoulou A, et al. Combination chemotherapy with carboplatin, paclitaxel and pegylated liposomal doxorubicin for advanced or recurrent carcinosarcoma of the uterus: clinical experience of a single institution. Gynecol Oncol. 2008;110:299–303.

    Article  CAS  PubMed  Google Scholar 

  84. van Rijswijk RE, Vermorken JB, Reed N, Favalli G, Mendiola C, Zanboni F, et al. Cisplatin, doxorubicin and ifosfamide in carcinosarcomas of the female genital tract. A phase II study of the European Organization for Research and Treatment of Cancer Gynaecological Cancer Group (EORTC 55923). Eur J Cancer. 2003;39:481–7.

    Article  PubMed  Google Scholar 

  85. Miller BE, Blessing JA, Stehman FB, Shahin MS, Yamada SD, Secord AA, et al. A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol. 2010;118:139–44.

    Article  CAS  PubMed  Google Scholar 

  86. Fowler JM, Blessing JA, Burger RA, Malfetano JH. Phase II evaluation of oral trimetrexate in mixed mesodermal tumors of the uterus: a gynecologic oncology group study. Gynecol Oncol. 2002;85:311–4.

    Article  CAS  PubMed  Google Scholar 

  87. Miller DS, Blessing JA, Schilder J, Munkarah A, Lee YC. Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol. 2005;98:217–21.

    Article  CAS  PubMed  Google Scholar 

  88. Curtin JP, Blessing JA, Soper JT, DeGeest K. Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol. 2001;83:268–70.

    Article  CAS  PubMed  Google Scholar 

  89. Manolitsas TP, Wain GV, Williams KE, Friedlander MF, Hacker NF. Multimodality therapy for patients with clinical stage I and II malignant mixed Mullerian tumours of the uterus. Cancer. 2001;91:1437–43.

    Article  CAS  PubMed  Google Scholar 

  90. Menczer J, Levy T, Piura B, Chetrit A, Altaras M, Meirovitz M et al. A comparison between different postoperative treatment modalities of uterine carcinosarcoma. Gynecol Oncol 2005;97:166-70. mullerian tumors of the uterus. Int J Gynecol Cancer 2006;16:1364-9.

  91. Wong L, See HT, Khoo-Tan HS, Low JS, Ng WT, Low JJ. Combined adjuvant cisplatin and ifosfamide chemotherapy and radiotherapy for malignant mixed mullerian tumors of the uterus. Int J Gynecol Cancer 2006;16:1364-9. 15.

  92. Gungorduk K, Ozdemir A, Ertas IE, Gokcu M, Telli E, Oge T, et al. Adjuvant treatment modalities, prognostic predictors and outcomes of uterin carcinosarcomas. Cancer Res Treat. 2015;47:282–9. In patients with early or advanced stage uterine carcinosarcoma adjuvant chemotherapy with radiotherapy is associated with improved disease free survival and overall survival as compared to chemotherapy or radiotherapy alone.

    Article  PubMed Central  PubMed  Google Scholar 

  93. Pacaut C, Bourmaud A, Rivoirard R, Moriceau G, Guy JB, Collard O, et al. Uterine and ovary carcinosarcomas: outcome, prognosis factors, and adjuvant therapy. Am J Clin Oncol. 2015;38:272–7.

    Article  CAS  PubMed  Google Scholar 

  94. Einstein MH, Klobocista M, Hou JY, Lee S, Mutyala S, Mehta K, et al. Phase II trial of adjuvant pelvic radiation “sandwiched” between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma. Gynecol Oncol. 2012;124:26–30.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  95. Huh WK, Sill MW, Darcy KM, Elias KM, Hoffman JS, Boggess JF, et al. Efficacy and safety of imatinib mesylate and immunohistochemical expression of c-kit and PDGFR-β in a gynaecologic oncology group phase II trial in women with recurrent or persistent carcinosarcomas of the uterus. Gynecol Oncol. 2010;117:248–54.

    Article  CAS  PubMed  Google Scholar 

  96. Nimeiri HS, Oza AM, Morgan RJ, Huo D, Elit L, Knost JA, et al. A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol. 2010;117:37–40.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  97. Campos SM, Brady WE, Moxley KM, O’Cearbhaill RE, Lee PS, DiSilvestro PA, et al. A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol. 2014;133:537–41.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  98. Yi-Shin Kuo D, Timmins P, Blank SV, Fields AL, Goldberg GL, Murgo A, et al. Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II Consortium. Gynecol Oncol. 2006;100:160–5.

    Article  CAS  PubMed  Google Scholar 

  99. Aghajanian C, Sill MW, Secord AA, Powell MA, Steinhoff M. Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2012;126:424–7.

    Article  CAS  PubMed  Google Scholar 

  100. Etoh T, Nakai H. Prognostic factors and status of hormone receptors andangiogenic factors in uterine carcinosarcoma. J Obstet Gynaecol Res. 2014;40:820–5.

    Article  CAS  PubMed  Google Scholar 

  101. Sho T, Hachisuga T, Nguyen TT, Urabe R, Kurita T, Kagami S, et al. Expression of estrogen receptor-α as a prognostic factor in patients with uterine serous carcinoma. Int J Gynecol Cancer. 2014;24:102–6.

    Article  PubMed  Google Scholar 

  102. Wang X, Tangjitgamol S, Liu J, Kavanagh JJ. Response of recurrent uterine high grade malignant mixed mullerian tumour to letrazole. Int J Gynecol Cancer. 2005;15:1243–8.

    Article  CAS  PubMed  Google Scholar 

  103. Amant F, Cadron I, Fuso L, Berteloot P, de Jonge E, Jacomen G, et al. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer. Gynecol Oncol. 2005;98:274–80.

    Article  PubMed  Google Scholar 

  104. Vaidya AP, Horowitz NS, Oliva E, Halpern EF, Duska LR. Uterine malignant mixed Mullerian tumors should not be included in studies of endometrial carcinoma. Gynecol Oncol. 2006;103:684–7.

    Article  CAS  PubMed  Google Scholar 

  105. Galaal K, Kew FM, Tam KF, Lopes A, Meirovitz M, Naik R, et al. Evaluation of prognostic factors and treatment outcomes in uterine carcinosarcoma. Eur J Obstet Gynecol Reprod Biol. 2009;43:88–92.

    Article  Google Scholar 

  106. Schiavone MB, Zivanovic O, Zhou Q, Leitao MM Jr, Levine DA, Soslow RA et al. Survival of patients with uterine carcinosarcoma undergoing sentinel lymph node mapping. Ann Surg Oncol 2015. doi:10.1245/s10434-015-4612-2.

  107. Harano K, Hirakawa A, Yunokawa M, Nakamura T, Satoh T, Nishikawa T et al. Prognostic factors in patients with uterine carcinosarcoma: a multi institutional retrospective study from the Japanese Gynecologic Oncology Group. Int J Clin Oncol 2015. doi:10.1007/s10147-015-0859-7.

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Joseph Menczer declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, E. Wolfson Medical Center, Holon, Israel

    Joseph Menczer MD

Authors
  1. Joseph Menczer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph Menczer MD.

Additional information

This article is part of the Topical Collection on Gynecologic Cancers

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Menczer, J. Review of Recommended Treatment of Uterine Carcinosarcoma. Curr. Treat. Options in Oncol. 16, 53 (2015). https://doi.org/10.1007/s11864-015-0370-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-015-0370-4

Keywords

Search

Navigation